Bicycle therapeutics announces first patient dosed in expansion cohorts of phase i/ii trial of bicycle® toxin conjugate bt5528 in patients with advanced solid tumors associated with epha2 expression

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the first patient has been dosed in the expansion portion of the phase i/ii study of bt5528, bicycle's second-generation bicycle toxin conjugate (btc™) targeting epha2. “we believe epha2 is an attractive target for cytotoxin delivery and bt5528 has
BCYC Ratings Summary
BCYC Quant Ranking